These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 16619247)
1. Molecular profiling of platinum resistant ovarian cancer: use of the model in clinical practice. Gevaert O; Pochet N; De Smet F; Van Gorp T; De Moor B; Timmerman D; Amant F; Vergote I Int J Cancer; 2006 Sep; 119(6):1511; author reply 1512. PubMed ID: 16619247 [No Abstract] [Full Text] [Related]
2. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer. Lee PS; Teaberry VS; Bland AE; Huang Z; Whitaker RS; Baba T; Fujii S; Secord AA; Berchuck A; Murphy SK Int J Cancer; 2010 Mar; 126(6):1378-89. PubMed ID: 19642140 [TBL] [Abstract][Full Text] [Related]
3. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060 [TBL] [Abstract][Full Text] [Related]
4. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma. Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581 [TBL] [Abstract][Full Text] [Related]
5. "Recurrence within 6 months of platinum therapy": an adequate definition of "platinum-refractory" ovarian cancer? Markman M Gynecol Oncol; 1998 May; 69(2):91-2. PubMed ID: 9600812 [No Abstract] [Full Text] [Related]
6. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686 [TBL] [Abstract][Full Text] [Related]
7. [Proteomic analysis of human ovarian cancer cell lines and their platinum-resistant clones]. Yan XD; Pan LY Zhonghua Fu Chan Ke Za Zhi; 2006 Sep; 41(9):584-7. PubMed ID: 17181965 [TBL] [Abstract][Full Text] [Related]
8. "Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit? Davis A; Tinker AV; Friedlander M Gynecol Oncol; 2014 Jun; 133(3):624-31. PubMed ID: 24607285 [TBL] [Abstract][Full Text] [Related]
9. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro. Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892 [TBL] [Abstract][Full Text] [Related]
10. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer. Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486 [TBL] [Abstract][Full Text] [Related]
11. Molecular profiling of platinum resistant ovarian cancer. Helleman J; Jansen MP; Span PN; van Staveren IL; Massuger LF; Meijer-van Gelder ME; Sweep FC; Ewing PC; van der Burg ME; Stoter G; Nooter K; Berns EM Int J Cancer; 2006 Apr; 118(8):1963-71. PubMed ID: 16287073 [TBL] [Abstract][Full Text] [Related]
12. Establishment of cisplatin-resistant ovarian yolk sac tumor cells and investigation of the mechanism of cisplatin resistance using this cell line. Shibata K; Umezu T; Sakurai M; Kajiyama H; Yamamoto E; Ino K; Nawa A; Kikkawa F Gynecol Obstet Invest; 2011; 71(2):104-11. PubMed ID: 21150160 [TBL] [Abstract][Full Text] [Related]
13. Deep transcriptome profiling of ovarian cancer cells using next-generation sequencing approach. Li L; Liu J; Yu W; Lou X; Huang B; Lin B Methods Mol Biol; 2013; 1049():139-69. PubMed ID: 23913215 [TBL] [Abstract][Full Text] [Related]
14. Unfavourable prognostic significance of S100P expression in ovarian cancers. Surowiak P; Maciejczyk A; Materna V; Drag-Zalesińska M; Wojnar A; Pudelko M; Kedzia W; Spaczyński M; Dietel M; Zabel M; Lage H Histopathology; 2007 Jul; 51(1):125-8. PubMed ID: 17539915 [No Abstract] [Full Text] [Related]
15. Differential gene expression studies in cisplatin-sensitive versus cisplatin-resistant human cancer cell lines. Gosepath EM; Weykam S; Gruenewald E; Ko Y; Wiese M; Kassack MU Int J Clin Pharmacol Ther; 2004 Nov; 42(11):637-9. PubMed ID: 15598029 [No Abstract] [Full Text] [Related]
17. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin. Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583 [TBL] [Abstract][Full Text] [Related]
18. Why does chemotherapy stop affecting the cells of ovarian and breast tumors? Kalinina EV; Chernov NN Future Oncol; 2018 May; 14(12):1137-1140. PubMed ID: 29629566 [No Abstract] [Full Text] [Related]
19. Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer. Yoshida H; Sumi T; Zhi X; Yasui T; Honda K; Ishiko O Anticancer Res; 2011 Apr; 31(4):1271-7. PubMed ID: 21508375 [TBL] [Abstract][Full Text] [Related]
20. Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines. Yan XD; Pan LY; Yuan Y; Lang JH; Mao N J Proteome Res; 2007 Feb; 6(2):772-80. PubMed ID: 17269733 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]